Navigation Links
Halo Pharma And Altus Formulation Announce New Formal Collaboration
Date:5/14/2013

MONTREAL, May 14, 2013 /PRNewswire/ -- Halo Pharma today announced that it has taken a minority ownership position in, and established a formal collaboration with, the drug formulation and development company Altus Formulation Inc. Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems.

Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or complex. On a fee for service basis Halo will always remain committed to practical facilitation and implementation of non proprietary and client based solutions to scientific and technical challenges in the areas of pre-formulation, analytical method development, formulation, scale up, regulatory submission and commercial manufacturing. These approaches typically generate significant new wholly client owned IP.

With this new investment in, and association with, Altus Formulations, Halo takes a first step in offering to clients, when needed, an entire suite of proprietary scientific and technical solutions designed to solve intractable issues in such areas as drug solubility, bioavailability, tamper and abuse deterrence, and precisely managed drug dosage delivery. These proprietary solutions cover a wide range of non-sterile and sterile dosage forms. One such area requiring solution is the currently much discussed question of the need for abuse resistance for narcotic analgesic and other frequently abused CNS drugs.

In commenting on the collaboration with Altus the CEO of Halo Pharma Clive Bennett said, "We are delighted to have this new association with Altus as it will allow Halo to provide novel proprietary solutions to clients with difficult formulation problems in addition to those already available public domain and client originated solutions that we have historically offered."

Damon Smith CEO of Altus Formulation remarked, "The Altus team is extremely excited to be collaborating with Halo Pharma with their track record of excellence in the contract development and manufacturing fields. By combining our strengths Altus and Halo offer a full range of development and delivery options that are ideally placed to meet the needs of the industry."

About Halo Pharma
Halo Pharma is a privately held company with operations in the New Jersey pharmaceutical corridor and in Montreal, Quebec. Halo is a significant provider of drug development and commercial manufacturing services to the pharmaceutical industry. The company provides the highest quality products and services to some of the world's leading pharmaceutical and biotechnology companies.

The development services of Halo cover the entire development cycle from preclinical to clinical trial materials to registration including project management, pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and validation at commercial scale. Commercial manufacturing covers post approval launch of new and established molecular entities through late product life cycle strategies.

A wide range of dosage forms is supported both in development and commercial manufacturing.

About Altus
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost effective new products for its clients. With a focus on an improved patient experience Altus technologies include Intellitab tamper and abuse resistant technologies, Contramid®, for high dosage product delivery, MicroSpheres Plus for taste-masked controlled release liquids and the PNDS micellar technology platform that enables delivery of insoluble small and large molecules via both oral and parenteral routes to achieve increased bioavailability and low volume intravenous administration.

Contramid is a registered trademark of Paladin Labs Inc. (TSX: PLB) Each of these technologies are under exclusive global license from Paladin. Halo and Paladin are both minority shareholders in Altus Formulation.

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements.

 


'/>"/>
SOURCE Halo Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas Joins the National Pharmaceutical Council
2. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
3. Research Solutions Launches New Software-as-a-Service Compliance Solution for Pharmaceutical Companies
4. Sunshine Act Compliance Simplified for Pharmaceutical Drug Manufacturers with New Medical ePrint Solution from Reprints Desk
5. Ferring Pharmaceuticals Inc. Adopts Local Morristown Playground
6. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
7. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
8. Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
11. GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... According to the 2016 home healthcare ... for affordable healthcare solutions as since the early 2000s, the ... countries like the US, the healthcare cost rose faster than ... price index inflation rate stood at an average of 2.04% ... 3.62% during the same time period. This can be attributed ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented in ...   The conclusions of the study point to ... with 90% of the m presenting duration ... percent of the patients had clinical benefit.   ... I study of plitidepsin in combination with bortezomib and dexamethasone in patients with ...
Breaking Medicine Technology:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... trip to the Dominican Republic on September 21, 2016. Dr. Gerard, who holds ... serves with ChiroMission, a not-for-profit organization promoting health and wellness in Third World ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... Facility In Milwaukee , Out patient Services To Begin In June , Aloria ... is pleased to announce the opening of Aloria Milwaukee, its first treatment facility ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... "ProText Layouts ... said Christina Austin - CEO of Pixel Film Studios. , ProText Layouts Vol. 3 ... Final Cut Pro X . With ProText Layouts, video editors can create an ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... The old ... causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed ... a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , So ...
(Date:5/24/2016)... ... May 24, 2016 , ... Since 1946, the doctors ... care. From the moment a patient arrives at the office, the staff will ... with each and every patient to create a complete dental treatment plan that is ...
Breaking Medicine News(10 mins):